Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials.
Fakhry C, Zhang Q, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Weber RS, Lambert L, Trotti AM 3rd, Barrett WL, Thorstad WL, Yom SS, Wong SJ, Ridge JA, Rao SSD, Spencer S, Fortin A, Raben D, Harris J, Le QT.
Fakhry C, et al. Among authors: barrett wl.
Cancer. 2019 Jun 15;125(12):2027-2038. doi: 10.1002/cncr.32025. Epub 2019 Mar 26.
Cancer. 2019.
PMID: 30913305
Free PMC article.
Clinical Trial.